Abstract：
Cancer immunotherapy is a field that garners significant interest, fueled by the clinical success of immune checkpoint inhibitors. In contrast to conventional cancer therapies, immunotherapies leverage the host\'s immune system by enhancing innate and adaptive immunity to control cancer progression. Despite these exciting advances, only a subset of patients respond to these drugs, and immunotherapies frequently result in immune-related toxicity. One approach to overcome these challenges is intratumoral administration of treatment to minimize systemic toxicities and maximize therapeutic effects. Intratumoral cancer therapies have shown similar or superior antitumor efficacy in both treated and distant untreated tumors, with a widely improved benefit-risk ratio over conventional therapeutic approaches. Herein, we review the current landscape of intratumoral cancer gene immunotherapy.
Immunotherapies are drugs designed to activate a patient’s own immune system to fight cancer. Research in this field has soared following the US FDA’s approval of the first class of these drugs. They work by blocking cancer cells’ ability to hide from the body’s immune system. Unfortunately, only some patients respond and many experience side effects when the medicine is delivered to the whole body. One approach to overcome these problems is to deliver these drugs directly into a patient’s tumor to limit side effects while maintaining the positive effects. In this review we describe the benefits of giving these types of drugs directly into tumors over whole-body administration. We summarize the current clinical data and explain the mechanisms behind each drug.
Immunotherapies are drugs designed to activate a patient’s own immune system to fight cancer. Research in this field has soared following the US FDA’s approval of the first class of these drugs. They work by blocking cancer cells’ ability to hide from the body’s immune system. Unfortunately, only some patients respond and many experience side effects when the medicine is delivered to the whole body. One approach to overcome these problems is to deliver these drugs directly into a patient’s tumor to limit side effects while maintaining the positive effects. In this review we describe the benefits of giving these types of drugs directly into tumors over whole-body administration. We summarize the current clinical data and explain the mechanisms behind each drug.
摘要：
癌症免疫疗法是一个引起人们极大兴趣的领域，由免疫检查点抑制剂的临床成功推动。与传统的癌症疗法相反，免疫疗法通过增强先天和适应性免疫来控制癌症进展，从而利用宿主的免疫系统。尽管取得了这些令人激动的进展,只有一部分患者对这些药物有反应，和免疫疗法经常导致免疫相关的毒性。克服这些挑战的一种方法是肿瘤内施用治疗以使全身毒性最小化并使治疗效果最大化。肿瘤内癌症治疗在治疗和远处未治疗的肿瘤中显示出相似或优异的抗肿瘤功效。与常规治疗方法相比，获益风险比得到了广泛改善。在这里，我们回顾了肿瘤内肿瘤基因免疫治疗的现状。
免疫疗法是旨在激活患者自身免疫系统以对抗癌症的药物。在美国FDA批准第一类此类药物后，该领域的研究激增。它们通过阻断癌细胞隐藏身体免疫系统的能力来发挥作用。不幸的是,当药物被输送到全身时，只有一些患者有反应，许多患者会出现副作用。克服这些问题的一种方法是将这些药物直接递送到患者的肿瘤中以限制副作用,同时保持积极作用。在这篇综述中，我们描述了在全身给药中直接将这些类型的药物给予肿瘤的益处。我们总结了当前的临床数据，并解释了每种药物背后的机制。
免疫疗法是旨在激活患者自身免疫系统以对抗癌症的药物。在美国FDA批准第一类此类药物后，该领域的研究激增。它们通过阻断癌细胞隐藏身体免疫系统的能力来发挥作用。不幸的是,当药物被输送到全身时，只有一些患者有反应，许多患者会出现副作用。克服这些问题的一种方法是将这些药物直接递送到患者的肿瘤中以限制副作用,同时保持积极作用。在这篇综述中，我们描述了在全身给药中直接将这些类型的药物给予肿瘤的益处。我们总结了当前的临床数据，并解释了每种药物背后的机制。
